G. Reinhart

发表

Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forward.

G. Gintant, R. Fryer, B. Cox, 2005, Current opinion in chemical biology.

Histamine in cardiac sympathetic ganglia: a novel neurotransmitter?

R. Fryer, G. Reinhart, T. Esbenshade, 2006, Molecular interventions.

Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study

J. Segreti, S. Rosenberg, H. Sham, 2004, Cancer Chemotherapy and Pharmacology.

Hypertension induced by chronic renal adrenergic stimulation is angiotensin dependent.

T. Lohmeier, G. Reinhart, C. Hord, 1995, Hypertension.

Influence of angiotensin on the early progression of heart failure.

T. Lohmeier, J. Montani, G. Reinhart, 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

Hypertension induced by blockade of ET(B) receptors in conscious nonhuman primates: role of ET(A) receptors.

C. Wegner, B. Cox, G. Reinhart, 2002, American journal of physiology. Heart and circulatory physiology.

Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.

M. Nakane, W. Noonan, G. Reinhart, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Role of Phosphorus and Vitamin D Analogs in the Pathogenesis of Vascular Calcification

M. Nakane, J. R. Wu-wong, S. Morgan, 2006, Journal of Pharmacology and Experimental Therapeutics.

Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates

N. Moss, S. Weldon, J. Parmentier, 2016, The Journal of Pharmacology and Experimental Therapeutics.

A 4 Identification and characterization of positive allosteric modulators of the natriuretic peptide receptor-A

R. Fryer, F. Levy, A. Cataliotti, 2017 .

Mitigation of Off-Target Adrenergic Binding and Effects on Cardiovascular Function in the Discovery of Novel Ribosomal S6 Kinase 2 Inhibitors

J. Madwed, R. Fryer, M. Kashem, 2012, Journal of Pharmacology and Experimental Therapeutics.

(−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a Novel ATP-Sensitive Potassium Channel Opener: Hemodynamic Comparison to ZD-6169, WAY-133537, and Nifedipine in the Anesthetized Canine

R. Fryer, Yanhui Hu, M. Gopalakrishnan, 2004, Journal of cardiovascular pharmacology.

Reduced Heart Size and Increased Myocardial Fuel Substrate Oxidation in ACC2 Mutant Mice

S. Wakil, L. Abu-Elheiga, Saumya Sharma, 2007, American journal of physiology. Heart and circulatory physiology.

Hemodynamic and renal responses to chronic hyperinsulinemia in obese, insulin-resistant dogs.

J. Hall, G. Reinhart, M. Brands, 1995, Hypertension.

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin‐mediated angioedema

J. Segreti, R. Fryer, J. Trevillyan, 2008, British journal of pharmacology.

Reduced cardiac contractile responsiveness to isoproterenol in obese rabbits.

R. Hester, G. Reinhart, J. Carroll, 1997, Hypertension.

The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P1) and Hypertension (S1P3) in Rat

R. Fryer, L. Patnaude, J. Horan, 2012, PloS one.

Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.

K. Longenecker, J. Segreti, H. Sham, 2006, Journal of medicinal chemistry.

Blood pressure regulation by ETA and ETB receptors in conscious, telemetry-instrumented mice and role of ETA in hypertension produced by selective ETB blockade.

R. Fryer, B. Cox, G. Reinhart, 2006, American journal of physiology. Heart and circulatory physiology.

Cardiovascular disease in chronic kidney failure: the role of VDR activators.

M. Nakane, R. Fryer, P. Kroeger, 2006, Current opinion in investigational drugs.

Differential Inhibition of Renin mRNA Expression by Paricalcitol and Calcitriol in C57/BL6 Mice

M. Nakane, R. Fryer, J. R. Wu-wong, 2007, Nephron Physiology.

Blunted natriuretic response to a high-sodium meal in obese dogs. Role of renal nerves.

J. Granger, G. Reinhart, H. Mizelle, 1994, Hypertension.

Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.

R. Fryer, K. Marsh, B. Cox, 2008, American journal of physiology. Heart and circulatory physiology.

Effect of autonomic agents on renin release in the turtle, Pseudemys scripta.

M. Cipolle, J. Zehr, G. Reinhart, 1986, The American journal of physiology.

Quantification and Comparison of Anti-Fibrotic Therapies by Polarized SRM and SHG-Based Morphometry in Rat UUO Model

R. Fryer, A. Fogo, S. Weldon, 2016, PloS one.

Endothelin and ET(A) receptors in long-term arterial pressure homeostasis in conscious nonhuman primates.

C. Wegner, B. Cox, G. Reinhart, 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.

D. Donnelly-roberts, G. Gintant, J. Sullivan, 2006, CNS drug reviews.

Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors.

R. Fryer, G. Nabozny, Akalushi Muthukumarana, 2011, Journal of pharmacological and toxicological methods.

EFFECTS OF INTRAVENOUS ABT‐870 (IRON (III)‐HYDROXIDE OLIGOSACCHARIDE) ON MEAN ARTERIAL PRESSURE AND HEART RATE IN THE ANAESTHETIZED BEAGLE: COMPARISON WITH OTHER IRON‐CONTAINING HAEMATINIC AGENTS

R. Fryer, Yanhui Hu, J. Melnick, 2005, Clinical and experimental pharmacology & physiology.

ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxgenase-2 Inhibitor

G. Carter, S. Surapaneni, K. Marsh, 2004, Journal of Pharmacology and Experimental Therapeutics.

Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists.

Thomas Fey, Robin Shapiro, Ju Gao, 2005, Journal of medicinal chemistry.

Tumour‐selective antivascular effects of the novel anti‐mitotic compound A‐318315: An in vivo rat regional haemodynamic study

J. Segreti, S. Rosenberg, H. Sham, 2010, Clinical and experimental pharmacology & physiology.

Pharmacological Characterization of the Novel Dihydropyridine Potassium Channel Opener, (9R)-9-(3-Iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the Regulation of Cardiovascular Function in Conscious and Anesthetized Beagle Dogs

C. Shieh, R. Fryer, M. Gopalakrishnan, 2005, Journal of cardiovascular pharmacology.

ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat.

A. Gomtsyan, E. Schweitzer, M. Williams, 2000, The Journal of pharmacology and experimental therapeutics.

Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

K. Longenecker, H. Sham, R. Fryer, 2006, Journal of medicinal chemistry.

Bcl-2 family proteins are essential for platelet survival

C. Tse, M. L. Smith, S. Rosenberg, 2007, Cell Death and Differentiation.

Strategic Integration of In Vivo Cardiovascular Models During Lead Optimization: Predictive Value of 4 Models Independent of Species, Route of Administration, and Influence of Anesthesia

R. Fryer, L. Chi, R. Dinallo, 2012, Journal of cardiovascular pharmacology.

Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.

G. Diaz, E. Bush, H. Sham, 2006, Journal of medicinal chemistry.

Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Jordi Villà-Freixa, Peter Sandner, Bernd J. Pichler, 2017, BMC Pharmacology and Toxicology.

Renal denervation supersensitivity revisited.

T. Lohmeier, G. Reinhart, H. Mizelle, 1998, The American journal of physiology.

Temporal influence of the renal nerves on renal excretory function during chronic inhibition of nitric oxide synthesis.

T. Lohmeier, G. Reinhart, H. Mizelle, 1997, Hypertension.

Atrial natriuretic peptide and sodium homeostasis in compensated heart failure.

T. Lohmeier, J. Montani, R. Didlake, 1996, The American journal of physiology.

Role of the renin-angiotensin system in mediating the effects of posture on renal function.

T. Lohmeier, G. Reinhart, 1996, The American journal of physiology.

Influence of the renal nerves on sodium excretion during progressive reductions in cardiac output.

R. Hester, T. Lohmeier, J. Montani, 1995, The American journal of physiology.

Systemic Activation of the Calcium Sensing Receptor Produces Acute Effects on Vascular Tone and Circulatory Function in Uremic and Normal Rats: Focus on Central versus Peripheral Control of Vascular Tone and Blood Pressure by Cinacalcet

M. Nakane, J. Segreti, R. Fryer, 2007, Journal of Pharmacology and Experimental Therapeutics.

A soluble guanylate cyclase activator protects from diabetic nephropathy beyond standard of care in the ZSF1 rat

R. Fryer, Kathleen A. Lincoln, S. Pullen, 2015, BMC Pharmacology and Toxicology.

Models of renal insufficiency: the anti-thy-1.1 model of acute proliferative glomerulonephritis.

B. Cox, G. Reinhart, 2001, Current protocols in pharmacology.

Role of renal nerves in mediating the hypertensive effects of nitric oxide synthesis inhibition.

J. Granger, G. Reinhart, C. Schnackenberg, 1996, Hypertension.

The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease

R. Fryer, M. McHugh, Kathleen A. Lincoln, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications

James C. Campbell, Dong I. Lee, M. Zaccolo, 2017, BMC Pharmacology and Toxicology.

Effects of BW245C, a prostaglandin dp receptor agonist, on systemic and regional haemodynamics in the anaesthetized rat

B. Cox, R. Moreland, G. Reinhart, 2005, Clinical and experimental pharmacology & physiology.

ABT-963, A Highly Potent and Selective Disubstituted Pyridazinone COX-2 Inhibitor

G. Carter, S. Surapaneni, M. Jarvis, 2004 .

Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.

Ju Gao, Anil Vasudevan, John K Lynch, 2006, Journal of medicinal chemistry.

Vitamin D analogs: novel therapeutic agents for cardiovascular disease?

G. Reinhart, 2004, Current opinion in investigational drugs.